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Introduction 
Recently, it has been shown that at least two states of pluripotency exist. Mouse embryonic 
stem cells (mESC) are considered to be naïve, while human embryonic stem cells (hESC) 
have the property of being primed.  It is known that the 2i condition (combined inhibition of 
the Mitogen-Activated Protein Kinase (MAPK) and Glycogen Synthase Kinase (GSK)3β 
pathways) supports the naïve state of ESC, and increases epiblast formation in mice and 
human blastocysts. Here, we set out to investigate if inhibition of the TGFβ pathway, an 
important signalling pathway to sustain pluripotency in primed ESC, increases the epiblast 
cell number in human blastocysts as well, and if it permits subsequent successful hESC 
derivation. 
 
Materials and Methods 
All patients donating research embryos for this project provided written informed consent.  
This study was approved by the local Ethical Committee (2009/281) and the Federal Ethical 
Committee for embryo research (Adv-030).  For the first experiment, 169 fresh day 3 spare 
human embryos were randomized into three different culture groups (i): Control Cook 
Blastocyst medium (CB), (ii): CB + SB431542 (TGFβ inhibitor; 10µM), (iii): CB + Activin A 
(TGFβ activator; 50 ng/mL). The embryos were cultured at 37°C, 6% CO2 and 5% O2. 
Blastocysts were scored at day 6 and fixed using 4% paraformaldehyde. 
Immunocytochemistry was performed for Nanog (epiblast marker) and Gata6 (hypoblast 
marker). For the derivation experiment, 103 DMSO frozen embryos were thawed and cultured 
in the presence or absence of SB431542 from day 3 to day 6 of development. After this initial 
embryo culture, day 6 blastocysts with both good and poor quality ICMs were plated on a 
MEF feeder layer, either in standard hESC medium or in hESC medium supplemented with 
SB431542. As such, we created three different conditions (i): control blastocysts that were 
plated in standard hESC medium, (ii): SB blastocysts that were plated in SB supplemented 
hESC medium, and (iii): SB blastocysts that were plated in control hESC medium. 
 
Results 
Immunostainings revealed that the number of NANOG positive ICM cells was significantly 
higher in the SB group compared to the control (12.0 ± 5.9 versus 6.1 ± 4.7), but not in the 
Activin A group (6.7 ± 3.7). There were no differences in GATA6 positive cells between the 
groups (8.8 ± 4.3, 7.2 ± 4.0 and 8.0 ± 4.6 resp.). 
Of the plated control blastocysts, 33.33% developed into initial outgrowths (PICMIs (Post-
ICM-Intermediates)), and 16.66% formed embryonic stem cell colonies. When SB treated 
blastocysts were plated in SB supplemented hESC medium, no stem cells could be derived. 
Six days after plating the SB blastocysts in standard hESC medium, one initial outgrowth was 
formed (12.5%). This resulted in a new embryonic stem cell line that could be kept in culture 
for at least 30 passages.  
 
Conclusions 
Our findings indicate that the number of NANOG positive ICM cells significantly increased 
after inhibiting TGFβ with SB431542. This outcome resembles the effect of 2i treatment of 
human and mouse embryos. Therefore we speculate that inhibition of TGFβ signalling could 
be a valid approach to derive naïve hESC. Moreover, we saw that SB treatment of human 
embryos permits the derivation of pluripotent hESC lines. 
